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Abstract
Primary aldosteronism (PA), the most common cause of secondary hypertension, is a well-recognized condition that can lead
to cardiovascular and renal complications. PA is frequently left undiagnosed and untreated, leading to aldosterone-specific
morbidity and mortality. In this review we highlight the evidence linking PA with other conditions such as (i) diabetes
mellitus, (ii) obstructive sleep apnea, and (iii) bone health, along with clinical implications and proposed underlying
mechanisms.
Introduction
Despite old beliefs that primary aldosteronism (PA) is
uncommon and warrants screening only when patients
present with hypertension and hypokalemia, it is now
believed that PA is in fact the most common cause of
secondary hypertension, accounting for 5–13% of the
hypertensive cohort, with an even higher prevalence among
those with resistant hypertension [1, 2]. This stems
from more efficient screening of this condition with the
widespread use of the aldosterone:renin ratio [3, 4]. It is
a disorder in which the adrenal cortex autonomously
produces excessive aldosterone leading to sodium and
water retention, resulting in a subsequent rise of blood
pressure (BP), and the downregulation of renin through
the renin-angiotensin-aldosterone system (RAAS) pathway
[5]. Aldosterone-producing adenoma (APA) and bilateral
hyperaldosteronism (BHA) are the most common causes of
PA, with the latter being more prevalent [4, 6]. Unilateral
adrenalectomy for APA can potentially cure and at least
improves hypertension, and the mineralocorticoid receptor
antagonist (MRA) administration for BHA effectively
controls hypertension in this condition [7, 8].
Once considered a relatively benign condition, PA has
been unequivocally shown to have effects beyond its
effects on BP levels [9, 10]. Hypertension alone could not
explain the higher adverse cardiovascular outcomes as
PA patients were found to have a higher cardiovascular
mortality compared with patients with essential hyperten-
sion (EH) despite being matched for cardiovascular risks
[11]. PA-directed therapy was able to reduce the excess
morbidity to a level comparable to subjects with EH,
regardless of the treatment modality [12, 13]. Subse-
quently, elevated aldosterone levels were shown to con-
tribute to the excess morbidity and mortality [14]. Recent
studies have shown that PA is associated with a myriad of
other co-morbidities, particularly cardiovascular and renal
injuries, which might play a role in contributing to the
elevated morbidity and mortality [15]. What is less certain
and less looked into is the association between PA and
several nonclassical associations, namely diabetes, bone
health, and sleep apnea.
Several large cardiovascular trials have suggested that
the interruption of the RAAS prevented the occurrence of
diabetes, raising the question of a link between PA and
insulin resistance and diabetes. Besides the usual cardio-
vascular risk factors, obstructive sleep apnea (OSA) is
known to contribute to the development of hypertension and
plays an important role in resistant hypertension. There is
high prevalence of OSA in resistant hypertension and it has
been suggested that aldosterone is the hormone responsible
for the resistant hypertension seen in this cohort of patients,
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